Issue Type: Balancing Innovation, Value, and Drug Prices

does this show up on site? or is this internal?
in challenge narrative

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Evaluating Industry’s Drug Pricing Claims

  • Production Plus Profit Pricing (P-quad) FAQ

  • Medicare Must Study Unproven, Expensive Alzheimer’s Drug

  • Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

  • Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle

  • After 4 Years of Trump, Medicare and Medicaid Badly Need Attention

  • The Drugs at the Heart of Our Pricing Crisis

  • Biosimilars: Market Changes do not equal policy success

  • Curbing Biologic Drug Spending with P-quad